EA201590693A1 - Ингибиторы gdf-8 - Google Patents
Ингибиторы gdf-8Info
- Publication number
- EA201590693A1 EA201590693A1 EA201590693A EA201590693A EA201590693A1 EA 201590693 A1 EA201590693 A1 EA 201590693A1 EA 201590693 A EA201590693 A EA 201590693A EA 201590693 A EA201590693 A EA 201590693A EA 201590693 A1 EA201590693 A1 EA 201590693A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gdf
- inhibitors
- methods
- patient
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Abstract
Описаны ингибиторы GDF-8 формулы (I)и их фармацевтически приемлемые соли, где значения n, R, R, R, R, X и Z определены в настоящем документе. Также представлены содержащие их фармацевтические композиции. Такие соединения и композиции применимы в способах ингибирования GDF-8 в клетке и в способах лечения пациента, страдающего от заболевания или нарушения, при котором пациент смог бы ощутить терапевтический эффект от увеличения массы или силы мышечной ткани.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261710449P | 2012-10-05 | 2012-10-05 | |
PCT/US2013/063585 WO2014055955A1 (en) | 2012-10-05 | 2013-10-04 | Gdf-8 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201590693A1 true EA201590693A1 (ru) | 2015-08-31 |
Family
ID=49474701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590693A EA201590693A1 (ru) | 2012-10-05 | 2013-10-04 | Ингибиторы gdf-8 |
Country Status (20)
Country | Link |
---|---|
US (3) | US9145433B2 (ru) |
EP (1) | EP2903978B1 (ru) |
JP (2) | JP6457942B2 (ru) |
KR (1) | KR20150072412A (ru) |
CN (1) | CN104837832B (ru) |
AU (1) | AU2013326867B2 (ru) |
BR (1) | BR112015007182A2 (ru) |
CA (1) | CA2887203A1 (ru) |
CL (1) | CL2015000851A1 (ru) |
EA (1) | EA201590693A1 (ru) |
IL (1) | IL238031A0 (ru) |
MA (1) | MA38050B1 (ru) |
MX (1) | MX2015004151A (ru) |
PE (1) | PE20150767A1 (ru) |
PH (1) | PH12015500719A1 (ru) |
SA (1) | SA515360229B1 (ru) |
SG (1) | SG11201502527UA (ru) |
TN (1) | TN2015000121A1 (ru) |
WO (1) | WO2014055955A1 (ru) |
ZA (1) | ZA201503041B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2729999C1 (ru) * | 2016-07-29 | 2020-08-13 | Шанхай Инли Фармасьютикал Ко., Лтд | Азотсодержащее гетероциклическое ароматическое соединение, способ его получения, фармацевтическая композиция на его основе и его применение |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201590693A1 (ru) * | 2012-10-05 | 2015-08-31 | Ригель Фармасьютикалс, Инк. | Ингибиторы gdf-8 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US10233170B2 (en) | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
JP6513105B2 (ja) | 2014-04-22 | 2019-05-15 | ウニヴェルズィテート バーゼル | トリアジン、ピリミジン及びピリジン誘導体の新規製造方法 |
CN103965190A (zh) * | 2014-05-20 | 2014-08-06 | 定陶县友帮化工有限公司 | 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CN103965192B (zh) * | 2014-05-20 | 2016-01-13 | 定陶县友帮化工有限公司 | 一种6-氯咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CN103965191A (zh) * | 2014-05-20 | 2014-08-06 | 定陶县友帮化工有限公司 | 一种6-溴咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CA2953177C (en) | 2014-06-23 | 2019-07-23 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
CN104402881B (zh) * | 2014-11-05 | 2016-04-20 | 定陶县友帮化工有限公司 | 一种3-醛基-6-溴咪唑并[1,2-a]吡啶-8-甲酸乙酯的合成方法 |
US9981944B2 (en) | 2015-02-20 | 2018-05-29 | Rigel Pharmaceuticals, Inc | GDF-8 inhibitors |
ES2789331T3 (es) | 2015-03-02 | 2020-10-26 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
PL3319959T3 (pl) | 2015-07-06 | 2022-02-14 | Alkermes, Inc. | Hetero-haloinhibitory deacetylazy histonowej |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
RU2744974C2 (ru) | 2015-08-26 | 2021-03-17 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
AU2016355196A1 (en) | 2015-11-19 | 2018-06-21 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
AU2016361441B2 (en) * | 2015-11-25 | 2021-08-12 | Convergene Llc | Bicyclic BET bromodomain inhibitors and uses thereof |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
RS62011B1 (sr) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
KR102507967B1 (ko) | 2016-09-09 | 2023-03-09 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도 |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US11491025B2 (en) | 2016-10-25 | 2022-11-08 | Elevation Spine, Inc. | Intervertebral implant and method of use |
US10961239B2 (en) | 2017-01-05 | 2021-03-30 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
WO2018132533A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10758370B2 (en) | 2017-06-30 | 2020-09-01 | Elevation Spine, Inc. | Interbody spacer and bone plate assembly |
SI3664802T1 (sl) | 2017-08-07 | 2022-10-28 | Alkermes, Inc. | Biciklični zaviralci histon deacetilaze |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
CN112225736B (zh) * | 2020-11-12 | 2022-04-15 | 山东省科学院菏泽分院 | 一种6-溴咪唑并[1.2-a]吡啶-3-甲醛的制备方法 |
WO2023131868A1 (en) * | 2022-01-07 | 2023-07-13 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of glut9 for treatment of disease |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW458977B (en) * | 1997-04-16 | 2001-10-11 | Abbott Lab | 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds |
EP1140083A4 (en) * | 1999-01-08 | 2004-01-02 | Smithkline Beecham Corp | NEW CONNECTIONS |
NZ513642A (en) | 1999-01-21 | 2004-02-27 | Metamorphix Inc | Growth differentiation factor inhibitors and uses therefor |
JP2001081087A (ja) * | 1999-09-13 | 2001-03-27 | Sankio Chemical Co Ltd | 新規な2−(2−ピリジル)ピリミジン誘導体 |
WO2001057040A1 (en) * | 2000-02-03 | 2001-08-09 | Abbott Laboratories | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
HUP0700086A2 (en) * | 2000-08-11 | 2007-05-29 | Eisai Co Ltd | 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them |
AU2001295026B2 (en) * | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
MXPA04003445A (es) * | 2001-10-15 | 2004-07-08 | Du Pont | Iminobenzoxazinas imnobenztiazinas e iminoquinazolinas para controlar pestes de invertebrados. |
JP2005531520A (ja) * | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
JP2007528362A (ja) | 2003-08-14 | 2007-10-11 | 旭化成ファーマ株式会社 | 置換アリールアルカン酸誘導体及びその用途 |
MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
US20070185152A1 (en) * | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
EP1973914A2 (en) * | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
WO2008006583A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
CN101522682A (zh) * | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
EP2121669A2 (en) * | 2007-01-30 | 2009-11-25 | Biogen Idec MA, Inc. | Furanone compounds and methods of making and using the same |
EP2134684B1 (en) * | 2007-04-16 | 2017-08-02 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
ATE522249T1 (de) * | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
WO2009032653A1 (en) * | 2007-08-31 | 2009-03-12 | Smith Kline Beecham Corporation | Inhibitors of akt activity |
CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
EP2211619A1 (en) * | 2007-10-18 | 2010-08-04 | Merck Sharp & Dohme Corp. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
KR101015858B1 (ko) * | 2008-06-26 | 2011-02-23 | 제일모직주식회사 | 유기 화합물, 및 이를 포함하는 유기 광전 소자 |
US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
CN102272262B (zh) * | 2008-12-30 | 2014-09-10 | 第一毛织株式会社 | 有机光电装置用新化合物和包括该化合物的有机光电装置 |
US8569316B2 (en) | 2009-02-17 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases |
JP2013515734A (ja) * | 2009-12-23 | 2013-05-09 | エラン ファーマシューティカルズ,インコーポレイテッド | ポロ様キナーゼの阻害薬としてのプテリジノン |
WO2011096196A1 (en) * | 2010-02-02 | 2011-08-11 | Oncotherapy Science, Inc. | Lsd1 for target genes of cancer therapy and diagnosis |
JP5675850B2 (ja) * | 2010-02-05 | 2015-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ヘタリール−[1,8]ナフチリジン誘導体 |
US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
BR112012033658A2 (pt) * | 2010-07-05 | 2016-11-29 | Merck Patent Gmbh | derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases |
EA201590693A1 (ru) * | 2012-10-05 | 2015-08-31 | Ригель Фармасьютикалс, Инк. | Ингибиторы gdf-8 |
-
2013
- 2013-10-04 EA EA201590693A patent/EA201590693A1/ru unknown
- 2013-10-04 EP EP13780264.1A patent/EP2903978B1/en active Active
- 2013-10-04 CA CA2887203A patent/CA2887203A1/en active Pending
- 2013-10-04 US US14/046,834 patent/US9145433B2/en active Active
- 2013-10-04 SG SG11201502527UA patent/SG11201502527UA/en unknown
- 2013-10-04 BR BR112015007182A patent/BR112015007182A2/pt not_active IP Right Cessation
- 2013-10-04 MX MX2015004151A patent/MX2015004151A/es unknown
- 2013-10-04 JP JP2015535846A patent/JP6457942B2/ja active Active
- 2013-10-04 WO PCT/US2013/063585 patent/WO2014055955A1/en active Application Filing
- 2013-10-04 CN CN201380063519.8A patent/CN104837832B/zh active Active
- 2013-10-04 PE PE2015000455A patent/PE20150767A1/es not_active Application Discontinuation
- 2013-10-04 AU AU2013326867A patent/AU2013326867B2/en not_active Ceased
- 2013-10-04 KR KR1020157011251A patent/KR20150072412A/ko not_active Application Discontinuation
-
2015
- 2015-03-27 TN TNP2015000121A patent/TN2015000121A1/fr unknown
- 2015-03-30 IL IL238031A patent/IL238031A0/en unknown
- 2015-03-31 PH PH12015500719A patent/PH12015500719A1/en unknown
- 2015-04-02 SA SA515360229A patent/SA515360229B1/ar unknown
- 2015-04-02 CL CL2015000851A patent/CL2015000851A1/es unknown
- 2015-04-29 MA MA38050A patent/MA38050B1/fr unknown
- 2015-05-04 ZA ZA2015/03041A patent/ZA201503041B/en unknown
- 2015-08-24 US US14/833,689 patent/US9518040B2/en active Active
-
2017
- 2017-07-13 US US15/366,981 patent/US9878992B2/en active Active
-
2018
- 2018-11-02 JP JP2018207133A patent/JP2019048841A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2729999C1 (ru) * | 2016-07-29 | 2020-08-13 | Шанхай Инли Фармасьютикал Ко., Лтд | Азотсодержащее гетероциклическое ароматическое соединение, способ его получения, фармацевтическая композиция на его основе и его применение |
Also Published As
Publication number | Publication date |
---|---|
EP2903978B1 (en) | 2022-12-07 |
EP2903978A1 (en) | 2015-08-12 |
IL238031A0 (en) | 2015-05-31 |
PH12015500719A1 (en) | 2015-05-18 |
KR20150072412A (ko) | 2015-06-29 |
CL2015000851A1 (es) | 2015-08-28 |
US20140107073A1 (en) | 2014-04-17 |
MA38050B1 (fr) | 2017-01-31 |
US9145433B2 (en) | 2015-09-29 |
BR112015007182A2 (pt) | 2017-07-04 |
US9878992B2 (en) | 2018-01-30 |
PE20150767A1 (es) | 2015-05-15 |
SG11201502527UA (en) | 2015-04-29 |
JP2019048841A (ja) | 2019-03-28 |
US9518040B2 (en) | 2016-12-13 |
WO2014055955A1 (en) | 2014-04-10 |
JP2016500671A (ja) | 2016-01-14 |
CN104837832B (zh) | 2019-04-26 |
SA515360229B1 (ar) | 2015-11-25 |
ZA201503041B (en) | 2017-11-29 |
US20160052909A1 (en) | 2016-02-25 |
CA2887203A1 (en) | 2014-04-10 |
AU2013326867B2 (en) | 2018-03-08 |
MA38050A1 (fr) | 2016-06-30 |
AU2013326867A1 (en) | 2015-05-21 |
TN2015000121A1 (en) | 2016-06-29 |
JP6457942B2 (ja) | 2019-01-23 |
US20170342048A1 (en) | 2017-11-30 |
MX2015004151A (es) | 2015-07-06 |
CN104837832A (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590693A1 (ru) | Ингибиторы gdf-8 | |
EA201590975A1 (ru) | Ингибиторы prmt5 и их применение | |
EA202090486A3 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
UA111841C2 (uk) | Сполуки бензотіазолу та їх фармацевтичне застосування | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201492166A1 (ru) | N-замещенные бензамиды и их применение в лечении боли | |
EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
EA201391568A1 (ru) | Новые производные имидазола, подходящие для лечения артрита | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201290860A1 (ru) | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата | |
UA111770C2 (uk) | Інгібітори бромдомену | |
NZ703064A (en) | Inhibitors of hepatitis c virus | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
EA201491247A1 (ru) | Производные дигидробензооксазина и дигидропиридооксазина |